Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

References

• Eyawo O, Franco-Villalobos C, Hull MW, et al; Comparative Outcomes And Service Utilization Trends (COAST) study. Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. BMC Infect Dis. 2017;17(1):174. doi:10.1186/s12879-017-2254-728241797
   PubMed Web of Science ®Google Scholar
• Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018 pii: S2352-3018(18)30043-2 Epub ahead of print. doi:10.1016/S2352-3018(18)30043-2
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse effects of anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil. 2010;17:491–501. doi:10.1097/HJR.0b013e328336a15020543702
   PubMed Web of Science ®Google Scholar
• Opsomer M, Dimitrova D, Verspeelt J, et al. Evaluation of cardiovascular disease risk in HIV-1–infected patients treated with darunavir. Drugs R D. 2018;18:199–210. doi:10.1007/s40268-018-0238-8.29992490
   PubMed Web of Science ®Google Scholar
• Costagliola D, Potard V, Lang S, et al. Is the risk of myocardial infarction in PLHIV associated with atazanavir or darunavir exposure? AIDS 2018: 22nd International AIDS Conference, 7 23–27; 2018; Amsterdam, Netherlands Abstract TUPEB087.
   Google Scholar
• Antinori A, Meraviglia P, d’Arminio Monforte A, et al. Effectiveness, durability and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization non-interventional study. Drug Des Dev Ther. 2016;10:1589–1603.
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.9824222018
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Ramachandran SV, Pencina MJ, et al. The Framingham heart study. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(Suppl 2):743–753. doi:10.1161/CIRCULATIONAHA.107.69957918212285
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.19414839
   PubMed Web of Science ®Google Scholar
• Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061–2068. doi:10.1001/jama.2013.28053224240933
   PubMed Web of Science ®Google Scholar
• Law M, Friis-Møller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data collection on Adverse events of anti-HIV Drugs (DAD) study. HIV Med. 2003;4:1–10.
   PubMedGoogle Scholar
• Law MG, Friis-Møller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218–230. doi:10.1111/j.1468-1293.2006.00362.x16630034
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293–298.1985385
   PubMed Web of Science ®Google Scholar
• Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–248. doi:10.1016/S0140-6736(14)60604-825042234
   PubMed Web of Science ®Google Scholar
• Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60:1278–1280. doi:10.1093/cid/civ01425595743
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512. doi:10.1210/jc.2006-219017456578
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CCH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–622. doi:10.1001/jamainternmed.2013.372823459863
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35:1373–1381. doi:10.1093/eurheartj/eht52824408888
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Raffetti E, Focà E, et al. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care. 2016;28(12):1551–1558. doi:10.1080/09540121.2016.119875027321070
   PubMed Web of Science ®Google Scholar
• Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J. 2015;9:23–37. doi:10.2174/187461360150901002325866592
   PubMedGoogle Scholar
• Martin-Iguacel R, Llibre JM, Friis-Møller N. Risk of cardiovascular disease in an aging HIV population: where are we now? Curr HIV/AIDS Rep. 2015;12(4):375–387. doi:10.1007/s11904-015-0284-626423407
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse effects of anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23:214–223. doi:10.1177/204748731557929125882821
   PubMed Web of Science ®Google Scholar
• Thompson-Paul AM, Lichtenstein KA, Armon C, et al. Cardiovascular disease risk prediction in the HIV outpatient study. Clin Infect Dis. 2016;63:1508–1516. doi:10.1093/cid/ciw61527613562
   PubMed Web of Science ®Google Scholar
• De Socio GV, Pucci G, Baldelli F, Schillaci G. Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study. BMC Infect Dis. 2017;17:414. doi:10.1186/s12879-017-2510-x28606059
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–315.11804985
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Raffetti E, Donato F, et al. Neutrophil to lymphocyte ratio and cardiovascular disease incidence in HIV-infected patients: a population-based cohort study. PLoS One. 2016;11(5):e0154900. doi:10.1371/journal.pone.015490027148878
   PubMed Web of Science ®Google Scholar
• Antinori A, Di Perri G, Meraviglia P, et al. P141 Metabolic safety during treatment with darunavir-based regimens in an Italian observational study. Poster presented at: International Congress of Drug Therapy in HIV Infection; 10 23–26; 2016; Glasgow, UK.
   Google Scholar
• Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735. doi:10.1056/NEJMoa06274417460226
   PubMed Web of Science ®Google Scholar
• Lundgren J, Mocroft A, Ryom L. Contemporary protease inhibitors and cardiovascular risk. Curr Opin Infect Dis. 2018;31(1):8–13. doi:10.1097/QCO.000000000000042529232276
   PubMed Web of Science ®Google Scholar
• Lambert CT, Sandesara PB, Hirsh B, et al. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. HIV Med. 2016;17(6):411–424. doi:10.1111/hiv.1234626611380
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV Outpatient Study. Clin Infect Dis. 2010;51:435–447. doi:10.1086/65514420597691
   PubMed Web of Science ®Google Scholar
• Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a U.S. health care system. J Acquir Immune Defic Syndr. 2010;55:615–619. doi:10.1097/QAI.0b013e3181f4b75220827215
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012;55(4):600–607. doi:10.1093/cid/cis48922610928
   PubMed Web of Science ®Google Scholar
• Helleberg M, Kronborg G, Larsen CS, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. Clin Infect Dis. 2013;57:314–321. doi:10.1093/cid/cit23223575194
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014;65:160–166. doi:10.1097/QAI.000000000000000924442222
   PubMed Web of Science ®Google Scholar
• Sabin CA, Ryom L, De Wit S, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27:2735–2748. doi:10.1097/01.aids.0000432457.91228.f323842128
   PubMed Web of Science ®Google Scholar
• Menshawy A, Ismail A, Abushouk AI, et al. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis. Arch Virol. 2017;162:2181–2190. doi:10.1007/s00705-017-3346-9.
   PubMed Web of Science ®Google Scholar
• May M, Sterne JAC, Shipley M, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol. 2007;36:1309–1318. doi:10.1093/ije/dym13517652317
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus–infected patients. Arch Intern Med. 2010;170(14):1228–1238. doi:10.1001/archinternmed.2010.19720660842
   PubMedGoogle Scholar
• Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702–710. doi:10.1056/NEJMoa02204812594314
   PubMed Web of Science ®Google Scholar